Navigation Links
BioVascular, Inc. Expands Executive Team
Date:2/26/2008

SAN DIEGO, Feb. 26 /PRNewswire/ -- BioVascular, Inc., a company focused on developing novel therapies targeting platelet-mediated diseases, today announced that it appointed Christopher M. Bussineau, Ph.D., to the position of vice president of pharmaceutical operations and Eric Karpinski to the position of vice president, business development and nonvascular operations.

"Dr. Bussineau and Mr. Karpinski each bring skill and experience to BioVascular that will allow us to advance our business objectives," said John Parrish, CEO of BioVascular. "With continuing clinical progress in our two compounds, we will be looking to Mr. Karpinski to advance partnership discussions. Dr. Bussineau will be invaluable for establishing the infrastructure needed for further clinical development and eventual commercialization."

Dr. Bussineau brings relevant experience to BioVascular in the areas of process development as well as clinical and commercial manufacturing. Prior to joining BioVascular, Dr. Bussineau served as vice president and general manager of Cambrex Bio Science Baltimore. Before that, he was senior director of technical operations for the Biopharmaceutical Division of Chiron Corporation, acquired by Novartis in 2006. Dr. Bussineau holds a Ph.D. in chemical engineering from Rice University and a B.A. in chemistry from the University of California, San Diego.

Mr. Karpinski has extensive experience in business development, venture financing and strategic planning in the biopharma industry. He joined BioVascular after six years as a venture capitalist with Forward Ventures where he drove the diligence and supported companies in the portfolio including Hypnion, sold to Eli Lilly for $315M; Novacardia, sold to Merck for $350M; Predix, sold to Epix Medical; and Adiana, sold to Cytyc. Prior to working at Forward Ventures, Mr. Karpinski held business development and strategic planning roles at Genentech, Epix Medical and the pharmaceutical consulting p
'/>"/>

SOURCE BioVascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Press attending the Project LIBERTY ... advantage of the people and events in Emmetsburg on ... available throughout the day. Additionally, we will do our ... DSM representatives as well as representatives from the local ... , Please remember to RSVP to Matt Merritt ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $2.1 million. The orders consist of three large odour control ... . "These orders are consistent with the ... Peter Bruijns , President and CEO. "After a difficult ... we are now beginning to see sales growth. Our lower ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... is available in its catalogue: India ... 2019 http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... corporations are the main governing bodies responsible for ... in cities. On an average, around 135,000 MT ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... study published in the September issue of ... a novel strategy to diagnose the leading cause ... structural damage has occurred. This advance involves quantifying ... the endothelium of retinal vessels. Using new probes ... the early molecular development of diabetic retinopathy. , ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... optogenetics, the researchers are able to target one cell ... to find out exactly what goes wrong in the ... Prof. Dr. Stefan Herlitze (RUB Department for Biology and ... Biological Chemistry . The Bochum team examined a specific ...
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... - Researchers speaking on the final day of the 6th ... 2011) have focused on the growing interest in the scientific ... have been growing over the past 12 months and are ... Society (IAS) convened working group concentrating its initial efforts on ...
Cached Biology News:Controlling movements with light 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 3 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 4
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
... Immunogen: Synthetic peptide derived from an ... protein. Specificity: Specific for the ... WNT2B/WNT13 proteins. Recognizes both human WNT13A ... Human Rat (positive controls: mouse WNT2B/WNT13-pCMV-tag2-transfected ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic ... the human C35 protein (chromosome 17 open ... Specificity: Specific for the C35 protein. ... band at ~15 kDa band. Reactivity: ...
...
Biology Products: